Changes to This Summary (02/18/2010)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information ¹

Added Arulogun et al. as reference 12 ².

Stage I Mycosis Fungoides/Sézary Syndrome ³

Added text ⁴ to include ultraviolet B radiation is under clinical evaluation as the third standard treatment option and symptomatic management with topical corticosteroids as the fourth standard treatment option.

Added Olsen et al. as reference 19 ⁴.

Stage II Mycosis Fungoides/Sézary Syndrome ⁵

Added text ⁶ to include ultraviolet B radiation is under clinical evaluation as the third standard treatment option and symptomatic management with topical corticosteroids as the fourth standard treatment option.

Added Quereux et al. as reference 17 ⁶ and Olsen et al. as reference 18 ⁶.

Stage III Mycosis Fungoides/Sézary Syndrome ⁷

Added text ⁸ to include ultraviolet B radiation is under clinical evaluation as the third standard treatment option and symptomatic management with topical corticosteroids as the fourth standard treatment option.

Added Scarisbrick et al. as reference 18 ⁸, Quereux et al. as reference 24 ⁸, and Olsen et al. as reference 25 ⁸.

Stage IV Mycosis Fungoides/Sézary Syndrome ⁹

Added text ¹⁰ to include ultraviolet B radiation is under clinical evaluation as the third standard treatment option and symptomatic management with topical corticosteroids as the fourth standard treatment option.

Added Scarisbrick et al. as reference 19 ¹⁰, Quereux et al. as reference 26 ¹⁰, and Olsen et al. as reference 27 ¹⁰.

Recurrent Mycosis Fungoides/Sézary Syndrome ¹¹

Added text ¹² to include additional electron-beam radiation or a repeat of total-skin electron-beam radiation therapy; photon radiation to bulky skin or nodal masses; topical treatment with mechlorethamine or psoralen and ultraviolet A radiation; ultraviolet B radiation and symptomatic management with topical corticosteroids as treatment options under clinical evaluation.